Ken Powell
PresidentGenesis Business Development
Ken Powell is the President of Genesis Business Development, a global healthcare consultancy. Mr. Powell has experience in the identification, acquisition, and commercialization of intellectual property, new businesses, and products in the medical device and clinical diagnostics market segments worldwide. He has extensive knowledge about emerging technologies, test kits, medical devices, clinical laboratory equipment, and molecular diagnostics market segments. Mr. Powell has held senior management positions with Becton Dickinson, Roche Diagnostics, Technicon, Armour Pharmaceuticals, and Upjohn Clinical Laboratory Procedures. He is conversant in all aspects of diagnostic and life sciences segments including product development, IP, valuation, technology assessment, manufacturing, finance, marketing, and sales. (This is me - Update Profile)
| 2006 - present | President Genesis Business Development |
|---|---|
| 1986 - 2006 | Director of Business Development Becton, Dickinson and Company |
| 1984 - 1986 | Director of Marketing Revlon Healthcare |
| 1982 - 1983 | Senior Product Manager Becton Dickinson Immunodiagnostics |
GLG Study Groups with Ken Powell(?)
| Study Group Name | Members |
|---|---|
| Illumina's SNP Chip Users (US) | 35 |
| Economic Experts on Managed Care | 607 |
| Pricing Experts on Clinical Lab Testing in the U.S. | 56 |
GLG NewsSM
Analyses by Ken Powell(?)
BD GeneOhm's recent CE Mark for its molecular diagnostic test for the rapid diagnosis of Clostridium difficile infection will likely intensify the competition between BD and Cepheid. Both companies market tests for the $1 billion dollar Methicillin-Resistant Staphylococcus Aureus (MRSA)&...
A new test form AspenBio could revolutionalize the diagnosis of appendicitis. Over 6 million patients present to Emergency Departments each year with abdominal pain, resulting in approximately 700,000 appendectomies. Over $5 billion is spent each year in the US on CT scans, the currently...
The House of Representatives repealed the Centers for Medicare and Medicaid Services (CMS) authority to conduct a competitive bidding demonstration program for laboratory services. Senate action is now required.
The sale of Datascope's (NASDAQ: DSCP) patient monitoring business earlier this year to Mindray Medical (NYSE: MR) has resulted in several acquisition offers from unnamed companies. On Wednesday, Datascope's stock increased 11% in response to this news.
GLG InstituteSM Seminars with Ken Powell(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Ken Powell
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms